An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-08-30
DOI
10.3389/fimmu.2022.955035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report
- (2022) Mariateresa Cantelli et al. Dermatologic Therapy
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
- (2022) Daniela Mikhaylov et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Successful treatment of chronic severe alopecia areata with abrocitinib
- (2022) Michaela Bennett et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- The current state of knowledge of the immune ecosystem in alopecia areata
- (2022) Samuel J. Connell et al. AUTOIMMUNITY REVIEWS
- Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study
- (2022) Simon de Lusignan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata
- (2022) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- (2022) Brett King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
- (2022) Léa Hoisnard et al. Scientific Reports
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice
- (2021) Zhenpeng Dai et al. Science Advances
- Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies
- (2021) Inge Lodewijckx et al. Pharmaceuticals
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- (2021) Özge Aşkın et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata
- (2021) Alessio Gambardella et al. Dermatitis
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- (2021) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hair follicle immune privilege and its collapse in alopecia areata
- (2020) Marta Bertolini et al. EXPERIMENTAL DERMATOLOGY
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- (2020) Jung Eun Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Factors associated with insurance coverage of tofacitinib for alopecia areata: a retrospective review from an academic institution
- (2020) Hannah J. Thompson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo
- (2020) Katarzyna Tomaszewska et al. Oxidative Medicine and Cellular Longevity
- Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases
- (2020) Sailish Honap et al. INFLAMMATORY BOWEL DISEASES
- Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
- (2020) Rebekka Jerjen et al. PEDIATRIC DERMATOLOGY
- JAK inhibitors and alopecia areata
- (2019) Amos Gilhar et al. LANCET
- PF-06651600, a dual JAK3/TEC family kinase inhibitor
- (2019) Hua Xu et al. ACS Chemical Biology
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
- (2019) Elise A. Olsen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- (2018) A. Jabbari et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- (2018) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study
- (2018) Laita Bokhari et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children
- (2018) Brittany G. Craiglow et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ruxolitinib for the treatment of severe alopecia areata
- (2018) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The molecular details of cytokine signalling via the JAK/STAT pathway
- (2018) Rhiannon Morris et al. PROTEIN SCIENCE
- Induction of alopecia areata in C3H/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma
- (2018) Jung-Min Shin et al. Scientific Reports
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- (2017) Amy Vandiver et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- (2017) Cheryl B. Bayart et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hypertriglyceridaemia and risk of coronary artery disease
- (2017) Željko Reiner Nature Reviews Cardiology
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- (2016) Ali Jabbari et al. EXPERIMENTAL DERMATOLOGY
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- (2016) John E. Harris et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata
- (2015) Xiaoting Zhang et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy
- (2015) Jianbao Gao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transfer of Alopecia Areata to C3H/HeJ Mice Using Cultured Lymph Node–Derived Cells
- (2015) Eddy H.C. Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Quality of life in patients with alopecia areata: a hospital-based cross-sectional study
- (2015) S. Janković et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer
- (2014) A. Mishra et al. CLINICAL CANCER RESEARCH
- Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
- (2014) Atsuo Tanimoto et al. INFLAMMATION RESEARCH
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- (2014) Brittany G. Craiglow et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
- (2013) Yasuko Furumoto et al. BIODRUGS
- Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages
- (2011) Wei Liao et al. NATURE IMMUNOLOGY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
- (2010) Lynn Petukhova et al. NATURE
- Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy
- (2009) N. Barahmani et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
- (2009) Xiaoyu Hu et al. IMMUNITY
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
- Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack
- (2007) Taisuke Ito et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now